Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 11 tags : Phase 2 save search
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
phase 2 drop trial authorized
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
Published: 2021-06-11 (Crawled : 13:15) - globenewswire.com
ATOS | $1.485 4.58% 4.38% 1.1M
|
Health Technology
|
| O: 10.07%
H: 0.22%
C: -3.79%
phase 2 approval
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.92%
H: 2.83%
C: -5.66%
covid treatment phase 2 phase 2/3 trial
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
FMTX | $20.01 -0.15%
|
Health Technology
|
| O: -6.42%
H: 0.0%
C: -12.91%
europe phase 1 phase 3 phase 2
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
SRRK 4 | $14.79 5.64% 5.34% 740K
|
Health Technology
|
| O: 1.04%
H: 6.0%
C: 5.47%
phase 2 potential research muscular atrophy
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
CRIS | $14.73 -0.81% -0.81% 5.8K
|
Health Technology
|
| O: -23.82%
H: 0.41%
C: -17.08%
myeloid leukemia ongoing phase 1 positive therapy leukemia phase 3 phase 2 syndros ca-4948 acute myeloid leukemia
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
PTGX S | $26.82 0.79% 0.78% 340K
|
Health Technology
|
| O: -0.33%
H: 19.95%
C: 17.52%
phase 2
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.49%
H: 0.03%
C: -0.61%
phase 2 europe als
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.74%
H: 0.07%
C: -0.81%
phase 2 results
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -3.51%
phase 2 positive results europe positive results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.